

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

15 October 2024

## **IXICO PLC**

("IXICO" or the "Company")

### **Result of Retail Offer**

Further to the announcement dated 8 October 2024, IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, is pleased to announce that, following the closing of the Retail Offer on the BookBuild platform on 14 October 2024, 516,244 New Ordinary Shares will be issued at the Issue Price of 9.5 pence per Retail Offer Share in connection with the Retail Offer, raising an additional £49,043.

Consequently, conditional on the passing of the Resolutions at the General Meeting, 41,315,792 Placing Shares, 789,472 Subscription Shares and 516,244 Retail Offer Shares, resulting in a total of 42,621,508 new Ordinary Shares, will be issued in relation to the Fundraising, raising total gross proceeds of £4.05 million.

### **Admission and Total Voting Rights**

Application has been made for the Retail Offer Shares to be admitted to trading on AIM ("Admission"). Admission is expected to take place at 8.00 a.m. on or around 28 October 2024.

The Retail Offer Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with existing Ordinary Shares including the right to receive all dividends and other distributions declared, made or paid after their date of issue.

Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 92,668,598 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 92,668,598. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.

For the purposes of UK MAR, the person responsible for arranging release of this announcement on behalf of the Company is Bram Goorden, Chief Executive Officer.

Capitalised terms used in this announcement have the meaning given to them in the Placing and Retail Offer announcement dated 8 October 2024, unless otherwise defined in this announcement.

### **For further information please contact:**

#### **IXICO plc**

Bram Goorden, Chief Executive Officer  
Grant Nash, Chief Financial Officer

+44 (0) 20 3763 7499

#### **Cavendish Capital Markets Limited**

##### **(Nominated adviser and sole broker)**

Giles Balleny / Dan Hodgkinson (Corporate Finance)  
Nigel Birks (Life Sciences Specialist Sales)  
Harriet Ward (Corporate Broking)  
Michael F Johnson / Tamar Cranford Smith (Sales)

+44 (0) 20 7220 0500

### **About IXICO**

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The

therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on [www.IXICO.com](http://www.IXICO.com) and follow us on X (formerly Twitter) @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROIUSUARSVURAUUA